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Since its discovery in 1967 [1], qualita tive hepatiti s B surface 
antigen (HBsAg) has been widely used for diagnosis of hepatiti s
B virus (HBV) infecti on. It took almost four decades until the 
developmen t of an automat ed reliable, speciﬁc and sensitive 
quantitative HBsAg assay (Architect™, Abbott Diagnosis, USA)
with a dynami c range of 0.05–250.0 IU/ml, and which is capable 
of detecting as low as 0.05 IU/ml HBsAg, correspondi ng to around 
0.2 ng/ml [2]. Another commerci ally available assay with compa- 
rable properties has recentl y been licensed (Elecsys HBsAg II
quant assay, Roche Diagnosti cs, USA) [3]. These assays detect 
the intact, wild type infectious virus as well as the two non-infec- 
tious forms of the envelope protei n, includin g the small, spheric 
surface protein (produced in excess of 104–105 over the infec- 
tious virion) and the ﬁlamentous-tubular particles containin g
the small, middle and large envelope proteins. The rising interest 
of the hepatol ogy commu nity in HBsAg quantiﬁcation is reﬂected
in over 60 reports, which appeared since the publicati on of Degu- 
chi et al. in 2004 [2,4–9]. Such assays have been used to study the 
pathophys iology, natural history, and response to therapeuti c
interventio ns in chronic hepatitis B (CHB). Indeed, HBsAg serum 
levels correlate with HBV replication and with intrahep atic 
cccDNA in HBeAg+ CHB patients. Furtherm ore, HBsAg levels have 
been shown to correlat e, although not completely, with serum 
HBV-DNA concentrati on. Thus, HBsAg derived from cccDNA has 
been suggested as low cost marker for follow-up of HBV replica- 
tion as compared to the signiﬁcantly more expensiv e HBV-DN A
assays. It should be remembered in this context that HBsAg can 
also be synthesized by integrated HBV-DN A into the host genome 
and this form of HBsAg is undisting uishable, by current methods,
from cccDNA encoded envelo pe protein(s). Regardl ess of this res- 
ervation, quantiﬁcation of HBsAg serum levels as a marker for 
viral burden and response to anti-viral therapy is progres sively 
being used, mainly in HBeAg + CHB patients. In such patients 
treated with pegylate d interferon with or without lamivud ine,
declining HBsAg levels may predict anti-HBe and the less fre- 
quent anti-HBs seroconve rsion. In contrast, although HBsAg lev- Journal of Hepato logy 20
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E-mail address: shouval@hadassah.org.il els tend to decline following seroconve rsion from HBeAg to
anti-HBe, the correlation between cccDNA, viral load and HBsAg 
levels in HBeAg negative patients is unpred ictable, especially in
view of the abundanc e of defective HBV particle s in such patients.
Recently Seto et al. have suggest ed a novel applicat ion for 
quantiﬁcation of serum HBsAg for the assessment of hepatic 
ﬁbrosis in HBeAg + CHB patients [10].They studied 140 patients 
in Hong-Kong (65% male, median age 32.7 years) of whom 56
(40%) had ALT 62  ULN. Seventy -two (51.4%) and 42 (30%)
had an Ishak ﬁbrosis score 61 and 87.9% were classiﬁed as in
the immun e clearance phase of persistent HBV infection . Patients 
with ﬁbrosis score 61, when compared to patien ts with ﬁbrosis
score >1, had signiﬁcantly higher median HBsAg levels (50,320
and 7820 IU/ml, respect ively, p <0.001). Among patients with 
ALT 62  ULN, serum HBsAg levels achieved an ROC analysis of
0.869 in predicting ﬁbrosis score 61. HBsAg P25,000 IU/ml was 
independen tly associated with ﬁbrosis score 61 (p = 0.025, odds 
ratio 9.042). Using this cut-off, HBsAg level in patients with ALT 
62  ULN, positive and negative predictive values (NPP) for pre- 
dicting a ﬁbrosis score 61 were 92.7% and 60.0% respectively . For 
an unidentiﬁed reason, HBV DNA levels had no associ ation with 
degree of ﬁbrosis establis hed through a liver biopsy. The investi- 
gators concluded that ‘‘Among HBeAg-po sitive patients with ALT 
62  ULN, high serum HBsAg levels can accurately predict ﬁbrosis
score 61, and could potentially inﬂuence decisions concerning treat- 
ment commencemen t and reduce the need for liver biopsy ’’.
In the present issue of the Journal of Hepatology , Martinot- 
Peignoux and co-workers from France have studied a larger,
and ethnically more diverse cohort of 406 Caucasian, Asian, Afri- 
can and Mediterranean CHB patients [11], extending and con- 
ﬁrming the preliminary observatio ns of Seto et al. regarding the 
inverse correlation between HBsAg levels and degree of ﬁbrosis
[10]. Both studies employ ed an identical quantitative HBsAg 
assay (Elecsys, Roche Diagnosti cs). However , while the report 
of Seto et al. included only HBsAg+/ HBeAg+ CHB patients of
unidentiﬁed genotype, the study of Martinot -Peignoux and co- 
workers recruite d both HBeAg positive (25%) and HBeAg negative 
(75%) patien ts. Of the 406 patients, 30% were of HBV genotyp e E,
26% genotype A, 24% genotyp e D, and 11–9% of genotype B and C,
respectively .
The main ﬁndings of the French study include: (1) a strong 
inverse correlation between HBsAg levels and degree of ﬁbrosis.
In contrast, no such correlation was present in the HBeAg nega- 
tive group. Thus, HBeAg+ CHB patients with moderat e or severe 13 vol. 58 j 1063–1064
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ﬁbrosis as assessed by the Metavir score, had signiﬁcantly lower 
serum HBsAg and HBV-DNA levels compared to patien ts with no
or little ﬁbrosis. (2) A strong correlation was found between 
HBsAg and HBV-DNA levels in the HBeAg+ group, but not in the 
HBeAg group. (3) Interestin gly, lower HBsAg levels and 
increased severity of ﬁbrosis were greater in patien ts with nor- 
mal ALT levels as compared to patients with elevated ALT. (4)
Importantly, 50% of the overall study population with cirrhos is
and 69% of the HBeAg+ cohort with cirrhosis belonged to geno- 
type A. (5) Genotype B patients had the highest HBsAg levels.
(6) Using ROC analysis, the overall ability of serum HBsAg levels 
to differentiate HBeAg+ patients into low (F0–F1) or moderate to
advanced ﬁbrosis (F2–F4) was calculated as 0.77 rising 0.89 in
patients with normal ALT. (7) HBeAg+ patients infected with 
genotype B or C could be separated into moderate and severe 
ﬁbrosis as compared to no or mild ﬁbrosis, using serum HBsAg 
levels alone withou t ALT. Thus, an overall cut-off value (irrespec-
tive of ALT) for serum HBsAg levels of 3.85 log IU/ml was calcu- 
lated for these genotypes at a theoretica l speciﬁcity of 86% and 
an NPP of 100%.
Comment: the study by Martinot -Peignoux and co-workers 
[11] indeed conﬁrms the associat ion between lower serum levels 
of HBsAg and the presence of moderate to severe ﬁbrosis in
HBeAg+ CHB patients as initially reported by Seto et al. [10].
The report is adding new information generated in a relativel y
large cohort of patients who also underwent genotyp ing for 
HBV. An in-depth comparis on between the two studies can be
found in the discussion in the report by Martino t-Peignoux 
et al. [11]. At present, the mechan ism, leading to a decreased 
HBsAg level in HBeAg+ patients with advanced ﬁbrosis is not 
understood . It was hypothesized that enhanced immune clear- 
ance of HBsAg or intracellular block of HBsAg secretio n may be
involved in such a process [10]. Regardl ess of the mechanism 
involved, the knowledg e that high HBsAg levels may predict 
insigniﬁcant ﬁbrosis in HBeAg+ patients is reassuri ng. However ,
despite its putative advantage and before embrac ing another 
method for assessment of hepatic ﬁbrosis, further validation of
these data is recommend ed. In particular , a comparis on with 
already availabl e means for assessment of ﬁbrosis (i.e., elastogra- 
phy) is warranted in a larger cohort of HBeAg + CHB patien ts with 
adequate represen tation of the individual genotyp es and ethnic 
groups. Finally, Tseng and co-workers have recently suggest ed
that in HBeAg- patients, high HBsAg levels can predict disease 
progression [12]. This observatio n stands in contrast to the 2 Journal of Hepatology 2013reports of Seto et al and Martinot-Peig noux et al [10,11]. The dif- 
ferent role of HBsAg quantiﬁcation in these two risk groups 
awaits further conﬁrmation and clariﬁcation.Conﬂict of interes t
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